Research Paper

ITGAE Defines CD8+ Tumor-Infiltrating Lymphocytes Predicting a better Prognostic Survival in Colorectal Cancer

Xiang Hu, Ya-Qi Li, Qing-Guo Li, Yan-Lei Ma, Jun-Jie Peng, San-Jun Cai

Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai 20032, China

A R T I C L E   I N F O

Article history:
Received 16 May 2018
Received in revised form 2 August 2018
Accepted 2 August 2018
Available online 9 August 2018

Keywords:
ITGAE
Tumor-infiltrating lymphocytes
Colorectal cancer
Prognosis

A B S T R A C T

Background: Tumor-infiltrating lymphocytes (TIL) in colorectal tumor tissue are significantly correlated with a favorable prognosis, such as CD8+ lymphocytes, which are also called tumor-reactive lymphocytes. However, not all tumor-infiltrating T cells confer benefit to patients. Therefore, it is of substantial benefit to identify a biomarker to demarcate these tumor-reactive lymphocytes.

Methods: We investigated whether ITGAE could be used to discriminate reactive CD8+ lymphocytes in colorectal cancer (CRC). TCGA colorectal cancer data sets (n1 = 492, n2 = 386) and FUSCC set (n3 = 276) were used in this study. Further phenotyping of ITGAE+ cells and the mechanistic basis were investigated.

Findings: In the training and testing sets from TCGA, ITGAE expression, which is strongly correlated with cytotoxic T cell markers (CD8/CD3/PD1), independently predicted longer disease-free survival (DFS) and overall survival (OS). In line with this, the association between ITGAE+ lymphocytes and survival has been confirmed in the FUSCC cohort for validation (P = .026). ITGAE + cells in the series always co-stained with CD8 were preferentially located in the tumor. Interestingly, ITGAE+ lymphocytes tended to associate with the epithelial–mesenchymal transition (EMT) with increased Snail and increased E-cadherin expression accompanied. Finally, gene set enrichment analysis showed that immune activation was significantly enriched in the high ITGAE+ TIL group, accompanied by enriched EMT-related pathways.

Interpretation: Because of the specified expression of tumor-reactive CD8+ T-cells, ITGAE may be a promising biomarker for the rapid identification of immune infiltration in CRC.

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Colorectal cancer is the fourth most common cancer worldwide, and its overall 5-year survival rate is approximately 50% [1]. In addition to pathological staging, histological subtype, and the extent of the surgical procedure, the presence of tumor-infiltrating lymphocytes (TIL) in surgically resected tumor tissue is also significantly correlated with a favorable prognosis [2]. Indeed, the accumulation of CD8+ TIL has been demonstrated to associate with an improved prognosis for patients in several malignances [3, 4]. In contrast, the presence of CD8 + TIL has not been consistently found to confer a survival benefit. Herein, a distinction has frequently focused on CD8+ TIL infiltrating the epithelial nests versus the surrounding stroma, while this approach has not been determined to identify the localization-related prognosis for CD8+ TIL [3, 5, 6]. In other words, the approach depending on the demarcation of epithelial and stromal regions is inaccurate and non-trivial in many malignances. Therefore, it is of substantial benefit to identify a biomarker for demarcating tumor-reactive cells.

Recent reports have suggested that ITGAE (integrin, alpha E), also named CD103, plays a vital role in anti-cancer immunity. For example, ITGAE can recognize aberrant cells via cytotoxic T cells in colon, lung and pancreatic cancer [7–9]. In addition, ITGAE+ T cells were identified as an effector memory phenotype [10]. Ultimately, ITGAE expression was profoundly upregulated in lymphocytes when TIL migrated to the tumor and co-engaged with TCR and TGF-β receptors at the site of the lesion [11]. Together, these observations led us to hypothesize that ITGAE expression might identify tumor-reactive cells that confer a favorable prognosis in colorectal cancers. Therefore, the aim of our study was to determine whether ITGAE+ TIL were associated with prolonged prognosis and whether the expression of ITGAE defined tumor-reactive CD8+ cells in colorectal cancers. Furthermore, we explored the mechanistic basis of our findings and whether the ITGAE+ TIL behaviors affected the epithelial–mesenchymal transition (EMT) to influence the patient’s outcome in CRC.
Research in context

Evidence before this study

It has been previously demonstrated that an improved prognosis for patients was associated with accumulation of CD8+ TIL in several malignancies. By contrast, presence of CD8 + CTL was not consistently found to confer survival benefit to patients. Therefore, it is of substantial benefit to identify a biomarker for demarcating tumor-reactive cells.

Added value of this study

The association between ITGAE + lymphocytes and survival has been confirmed in the TCGA and FUSCC cohorts. ITGAE + cells in the series always co-stained with CD8 were preferentially located in the tumor. Interestingly, ITGAE + lymphocytes tended to associate with the epithelial–mesenchymal transition (EMT) with decreased Snail and increased E-cadherin expression accompanied.

Implications of all available evidence

ITGAE + CD8 + lymphocyte infiltration plays a vital role in the antitumor immune response, and ITGAE has been identified as a biomarker of tumor-reactive CD8 + TIL.

2. Methods

2.1. Study Population

This study included three independent cohorts of CRC patients. The discovery cohort enrolling 492 CRC and testing sets including 386 consecutive patients, were obtained from the Cancer Genome Atlas (TCGA) database available from Cancer Genomics Browser of the University of California Santa Cruz (https://genome-cancer.ucsc.edu/). The pattern of ITGAE expression relative to that of other immunomarkers [12] was directly visualized with a heatmap using GraphPad Prism. The validation set enrolling 276 CRC patients was obtained from Fudan University Shanghai Cancer Center (FUSCC) between 2007 and 2009. Only patients with fully characterized tumors, intact overall survival (OS) or disease-free survival (DFS) were included. All patient data were collected, such as: age at the diagnosis, race, tumor localization, diagnostic year, tumor diameter, histological grade, number of lymph nodes retrieved, post-operative multimodal treatment (adjuvant chemotherapy or radiation), details of surgical procedures, complications rate, postoperative histopathology, and follow-up information (date of last visit, tumor relapse, tumor-related or unrelated death, overall survival: OS and disease-free survival: DFS). All patients from the FUSCC dataset provided written informed consent. The research protocol was reviewed and approved by the institutional review board of the FUSCC.

2.2. Tissue Microarray (TMA) Construction and Immunohistochemistry (IHC) Staining

In all, 276 unselected, non-consecutive, primary colorectal cancers were enrolled from January 2007 to November 2009 in FUSCC to construct the tissue microarray(TMA). Construction of this TMA has been previously described in detail [13]. Briefly for IHC, after deparaffinization of tissue blocks, antigen retrieval was performed in antigen retrieval solution at 100 °C for 15 min. Then primary antibody incubation were performed with one appropriate antibody [anti-ITGAE antibody (1:200), Snail antibody (1:400) from Abcam; anti-CD3e(1:200), CD68a(1:200), FOXP3(1:400), E-cadherin(1:400), CD56(1:800) from Cell Signaling Technology] overnight at 4 °C, respectively. Secondary antibody, anti-rabbit/mouse horse radish peroxidase (HRP) (Gene Tech, China), was applied and hematoxylin was used for counterstaining for 1 h. The number of positive cells per field was estimated using Image-Pro Plus 6.0 (Media Cybernetics Inc., Bethesda, MD, USA). The immunostaining was evaluated by two oncologists blinded to the clinical information. The cutoff values for survival analysis were determined by X-Tile 3.6.1 software 11 (Yale University, New Haven, CT, USA).

Regarding EMT markers, the staining intensity was scored as 0 (negative), 1 (weak), 2 (medium) or 3 (strong). The extent of staining was scored as 0 (<5%), 1(5–25%), 2 (26–50%), 3 (51–75%) and 4 (>75%) according to the percentage of the positive staining area in relation to the whole carcinoma area. We multiplied the percentage score by the staining intensity score to generate the immunoreactivity score (IRS). E-cadherin was scored as negative (final score ≤ 2) and positive (final score ≥ 3), and Snail was scored as negative (final score ≤ 2) and positive (final score ≥ 3), respectively.

2.3. Immunofluorescent Analysis of ITGAE + cells Phenotype

Antigen retrieval and incubation with the primary antibody of the full tumor were performed as described for TMA above. Then, Alexa Fluor 488 and 594 or goat anti-rabbit or mouse (1:200, Invitrogen) was used as the secondary antibody for an hour at room temperature. Ultimately, nuclei were stained with DAPI for 5 min when necessary. Fluorescence images were photographed with a fluorescence microscope. Within each tumor core, single positive (ITGAE or CD8) cells as well as double-positive (ITGAE and CD8) cells were counted manually.

2.4. Gene Set Enrichment Analysis (GSEA) and Differential Expression Analysis

GSEA was carried out to determine the pathways that were significantly enriched between low and high ITGAE + lymphocyte infiltration samples [14]. One thousand random sample permutations were performed. If we identified a gene set with a positive enrichment score, the set was defined as “enriched” when the majority of its members were highly expressed accompanied by a higher risk score.

We used edge R to analyze the differential gene expression. Significantly altered genes between low and high ITGAE + lymphocyte infiltration samples were defined as expressed genes with FDR-adjusted p-value<.05 and a change of at least two-fold.

2.5. Statistical Analysis

Statistical evaluation was performed using IBM SPSS statistics Version 22 (SPSS Inc.; IBM Corporation Software Group, Somers, NY, USA). All quantification data are presented as mean ± s.d. Statistically significant differences were determined by one-way ANOVA test and Student's t-test. All statistical tests were two-sided, and P-values <.05 were considered to be statistically significant. OS and DFS were estimated with the Kaplan-Meier method, and the log-rank (Mantel-Cox) test was used to compare independent subgroups. Cox proportional hazard models were used to investigate the effect on survival of multivariable relationships among covariates, including the age at diagnosis, gender, stage at diagnosis, histological type, histological grade and treatment. Stage, status of perineural and vascular invasion or any known clinical characteristics that could affect the prognosis were the stratified variables. Hazard ratios (HRs) and 95% confidence intervals (CIs) for multivariate analyses were computed using the Cox proportional hazard regression models.
3. Results

3.1. Predictive Value of ITGAE and Association with an Immune Signature in TCGA

To explore the utility of ITGAE as a biomarker of a tumor-reactive lymphocyte response in colorectal cancer, we first assessed the distribution pattern of ITGAE mRNA in the Cancer Genome Atlas (TCGA) colorectal cancer data set. ITGAE expression was found to be closely correlated with the expression levels of reactive tumor lymphocyte markers (CD3e-g, CD2), exhaustion molecules (PD1, TIGIT), antigen-presenting molecules (HLA-DRA1, HLA-DQB1, HLA-DQA1) and B cell biomarkers (CD19). Therefore, increased ITGAE expression stratified the immunologically “hot” tumors in the colorectal cancer cohort (Fig. 1a).

In the discovery set (TCGA), we used the X-tile program to determine the cut-off value of the ITGAE mRNA levels in tumor tissue:
1.847. Then, patients with high and low levels of ITGAE expression were identified for further analysis (≤ 1.847 for the low ITGAE group and > 1.847 for the high ITGAE group). Kaplan–Meier survival analysis was carried out to compare overall survival (OS) according to ITGAE expression, and significantly improved OS was found in the high ITGAE group (Fig. 1 b1, log-rank test = 4.721, P = .03). Furthermore, a much stronger association of ITGAE expression with regard to patient survival and prognosis was observed in the right-side colon cancer group (Fig. 1 b2, log-rank test = 5.581, P = .018).

In the testing set (TCGA), we observed a prolonged relapse-free survival of 2718 days in the high ITGAE expression group versus 2653 days in the low ITGAE expression group, although no significance was seen (Fig. 1 c1, log-rank test = 1.413, P = .235). Notably, in the right-side colon cancer group, high ITGAE expression was significantly associated with significantly improved relapse-free survival (Fig. 1 c2, log-rank test = 5.966, P = .015). The baseline characteristics of the patients in TCGA were found in supplementary Table 1.
Fig. 2. ITGAE+ infiltration is closely associated with survival in validation set from FUSCC. (a1) Overall survival (OS) and (a2) disease-free survival (DFS) of patients in FUSCC according to high or low infiltration of ITGAE+ cells. (b1) OS and (b2) DFS of patients in FUSCC according to high or low infiltration of CD8+ cells. (c1) OS and (c2) DFS of patients in FUSCC according to high or low infiltration of CD8+/ITGAE- cells.
increase E-cadherin expression (Table 4). Fluorescent microscopy demonstrated that ITGAE+ TILs in colorectal cancer were accompanied by an increase in E-cadherin expression (Table 4). Fluorescent microscopy demonstrated that ITGAE+ TILs in colorectal cancer were accompanied by increased infiltration of activated T cells and enhanced the expression of numerous cytokines and chemokines relative to immune cells, which also explained that patients with high ITGAE+ lymphocyte infiltration had longer survival times than those with low ITGAE+ lymphocyte infiltration. Interestingly, additional EMT-related pathways were associated with the ITGAE+ lymphocytes group (Fig. 6 c1-c2), including IL2-STAT5 and IL6-JAK-STAT3 signaling. JAK/STAT signaling is essential for the epithelial–mesenchymal transition in cancer cells. These results suggested that the recruitment of ITGAE+ lymphocytes was associated with the modulation of EMT in CRC, which was consistent with altered E-cadherin expression.

### 4. Discussion

Utilizing these three independent sets of colorectal cancers, we demonstrated that infiltrating ITGAE+ lymphocytes were closely associated with survival in colorectal cancer patients. Moreover, ITGAE can be regarded as a potential biomarker to discriminate the active phenotype of CD8+ lymphocytes in CRC. Using correlation analysis, ITGAE+ lymphocyte infiltration was not only accompanied by active CD8+ lymphocyte recruitment but also inherently associated with EMT. These results explained that patients with high ITGAE+ lymphocyte infiltration had longer survival times than those with low ITGAE+ lymphocyte infiltration.

ITGAE+ lymphocytes are an important component of the colorectal cancer microenvironment and are positively associated with survival, as demonstrated in this study. To explain this, the increase in ITGAE showed simultaneous T cell activation. With regard to the phenotype and ontology of ITGAE+ lymphocytes in human malignancies, diversity remains. In lung cancer patients, the role of ITGAE integrin was
demonstrated in lung tumor-infiltrating lymphocyte (TIL) clones to enhance specific TCR-mediated tumor cell cytotoxicity [16]. ITGAE+ lymphocytes were characterized by tissue-resident memory T cell transcriptomic and phenotypic signatures. More importantly, PD-1 and Tim-3 checkpoint receptors were frequently co-expressed simultaneously with ITGAE, thus increasing immune-induced cell death and modulating specific cytolytic activity toward autologous tumor cells upon blocking the PD-1/PD-L1 interaction. In pancreatic cancer, ITGAE+ lymphocytes were defined as activated cytolytic lymphocytes contributing to tumor lysis, as well as the maturation of the cytotoxic immune synapsis [8, 9, 17]. In addition, cytotoxic T lymphocytes from CD103 elevated tumors displayed features of enhanced cytotoxicity, then predicted a better survival prognosis in lung cancer [30]. In this study, we also demonstrated dominant ITGAE and CD8 co-staining in colorectal cancer and normal epithelium, while the precise differentiation status has not been explored. ITGAE may play a role in programming CD8+ T cell residency [31]. As the colorectal epithelium functions as a barrier against pathogens, we extrapolated that tissue-resident memory T cells may also be characterized by ITGAE. However, in the niche of tumor-specific immune responses, the majority of ITGAE+ lymphocytes are likely tumor-reactive and potentially tumorlytically infiltrating lymphocytes.

Fig. 3. ITGAE demarcates CD8+ TIL in colorectal cancer tissue. (a) Representative image of tissue from a colorectal cancer stained with DAPI (DNA, blue), anti-CD8 (green), anti-ITGAE (red) and double CD8/ITGAE+ (orange). (b) Representative images of CD8+ and ITGAE+ cells in the epithelial or stromal areas. (c-d) Representative image of tissue from a colorectal cancer stained with DAPI (DNA, blue), anti-CD3, anti-Foxp3 (green), anti-ITGAE (red). (e) Representative image of tissue from a colorectal cancer stained with DAPI (DNA, blue), anti-CD56 (green), anti-ITGAE (red); (f) Quantification of total CD8+, CD8+/ITGAE+ and CD8+/ITGAE- cells in the tumor tissue (n = 276). The Quantification was determined by one-way ANOVA. (g) The correlation of CD8+ and ITGAE+ cells. The statistical test was used for linear logistic regression analyses.
More importantly in this study, a close correlation between elevated ITGAE+ lymphocyte infiltration and improved survival of CRC was demonstrated with no need to discriminate their location in epithelial or stromal regions. Our findings implied that active CD8+ TIL in CRC was demarcated by the expression of ITGAE and suggested that these cells were induced and recruited as a result of the tumor immune response. Consistent results were observed in ovarian cancer, and ITGAE+ lymphocytes were also linked with prolonged patient survival, serving as a predicting marker to enrich the most beneficial subsets of TILs for the immuno-response [18]. In cervical cancer, dense ITGAE+ lymphocyte infiltration was strongly associated with a better prognosis than low ITGAE+ lymphocyte infiltration, and ITGAE seemed to be a more precise predictor of outcome than CD8 [19]. Meanwhile, increased numbers of ITGAE+/CD8+ TIL were resided frequently in microsatellite instability (MSI) colorectal cancers, which may contribute improved prognosis [32]. These results suggested that ITGAE alone may be considered an excellent biomarker for tumor-reactive T cells in CRC. Conversely, not all correlations between total CD8+, CD3+, CD45+ or FOXP3+ TIL and patient survival were observed, unless they were located in specific tumor regions, even though inconsistency remained. Thus, ITGAE identified a subpopulation of CD8+ T cells with a reactive phenotype that more accurately predicted patient outcome. In addition, through GSEA, we found that the infiltration of dense ITGAE+ lymphocytes was associated with the positive regulation of the inflammatory response, interferon alpha and gamma activation in CRC patients. Furthermore, cancers with high ITGAE+ lymphocytes exhibited significantly increased levels of interferon-response chemokines (CXCL9–10, and CXCL11), which contributed to the modulation of the migration of activated T cells, NK cells and enhanced the anti-tumoral response [20–22]. These results suggested that high ITGAE+ lymphocytes correlated with immune activation in the niche of CRC. Therefore, ITGAE+ lymphocytes might serve as an independent prognostic factor in stratifying and selecting colorectal patients with prolonged survivals.

The tumor-associated immune niche was significantly correlated with EMT. As in gastric cancer, an inflammatory microenvironment

![Image](https://example.com/image)

**Fig. 4.** ITGAE demarcates CD8+ TIL in normal colorectal epithelial tissue. (a) Representative image of normal colorectal epithelial tissue stained with DAPI (DNA, blue), anti-CD8 (green), anti-ITGAE (red) and double CD8/ITGAE+ (orange). (b) Representative images of CD8+ and ITGAE+ cells in the epithelial areas. (c) Representative image of tissue from a colorectal cancer stained with DAPI (DNA, blue), anti-CD3 (green), anti-ITGAE (red).

| Table 4 Correlation between ITGAE+ TIL and expression of EMT markers in colorectal cancer (Spearman rank test). |
|---|
| variables | ITGAE+ TIL |
| | Low infiltration | High infiltration | P value |
| E-cadherin | low | 72 | 45 | 0.003 |
| | high | 69 | 90 | |
| Snail | low | 77 | 99 | 0.001 |
| | high | 64 | 36 | |
that recruits macrophages can contribute to EMT by secreting transforming inducers such as TNF-α, TGF-β, TGF-α, and IL-6 [23, 24]. However, the modulation of EMT by the tumor immune microenvironment was poorly explored. The majority of reports so far have focused on the M2-like macrophage phenotype, which was first proven to induce tumor metastasis and EMT [25, 26]. In this study, ITGAE+ lymphocytes were found to be associated with increased E-cadherin expression and accompanied by decreased Snail expression. E-cadherin belongs to the cell adhesion molecule, whose expression on the membrane has been regarded as the hallmark of EMT [27]. It demonstrated that ITGAE+ lymphocytes had the potential to fight against malignant cells with EMT traits. However, it is still unclear whether immune cells could eliminate aberrant cells with EMT traits or support tumor cells to become more EMT-like.

Our study also has limitations. The primary limitation concerns the TMA approach, which may only partly evaluate tissue and tumor heterogeneity. However, our analyses have shown that duplicate TMA cores are sufficient to overcome sampling bias [28, 29]. In addition, two independent TCGA sets were utilized to find an almost perfect agreement concerning ITGAE+ lymphocyte infiltration. Still, variations in the amount of tumor stroma and epithelium among different tumors might have confounded the results. Our study included only patients with resected cancers, which might also induce the biased exclusion of unresectable patients.

Taken together, we demonstrated for the first time that ITGAE+ CD8+ lymphocyte infiltration plays a vital role in the antitumor immune response, and ITGAE has been identified as a biomarker of tumor-reactive CD8+ TIL. In this mechanism, ITGAE+ lymphocytes may even associate with interferon-response chemokines and EMT signaling and then serve as an independent predictor in colorectal cancers. Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2018.08.003.

Representative images of tissue cores as high (a), or low infiltration (b).

Fig. 5. The association between ITGAE+ TIL and EMT markers in CRC. Representative image of colorectal cancer tissue in (a) high ITGAE+ T cells (red) with high level of E-cadherin (green), compared with the low ITGAE+ T cells (red) with low expression of E-cadherin (green) (b). (c-d) Representative image of ITGAE+ T cells (green) negatively associated with level of Snail (red).
Fig. 6. ITGAE+ lymphocytes associated biologic pathways and processes. (a) Volcano plot comparing the FDR versus fold-change for genes from high-ITGAE+ TIL group relative to low-ITGAE+ TIL group. (b1-b3, c1-c2) lymphocyte activation and EMT-related pathways were enriched in the ITGAE+ lymphocytes group.
Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant No. NSFC1631).

Funding

No

Availability of Data and Materials

Not applicable.

Authors’ Contributions

Conceived and designed the experiments: H.X. and C.S.J. Analyzed the data: H.X., L.Y.Q., C.S.J., L.Q.G. Contributed reagents/materials/analysis tools: H.X., P.J.J and M.Y.L. Wrote the paper: H.X. and L.Y.Q.

Competing Interests

The authors declare that they have no competing interests.

Funding

No

Sources of Funding for Research

No

References

Siegel, R., Desantis, C., Jemal, A., 2014. Colorectal cancer statistics, 2014. CA Cancer J Clin 64, 104–117.

Marisa, L., Svorcz, M., Collura, A., Becht, E., Cervera, P., Wangnerd, K., et al., 2018. The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of Colon tumors. J Natl Cancer Inst 110.

Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., et al., 2001. Proliferative Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61, 5132–5136.

Kondratiev, S., Sabo, E., Yakirevich, E., Lavie, O., Resnick, M.B., 2004. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 10, 4450–4456.

Donnern, T., Hald, S.M., Paulsen, E.E., Richardsen, E., Al-Saad, S., Klvaer, T.K., et al., 2015. Stromal CD8+ T-cell density—a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res 21, 2635–2643.

Lohnies, P., Sinn, M., Bischoff, S., Juhring, A., Pelzer, U., Wislocka, L., et al., 2017. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer 83, 290–301.

Ling, K.L., Dulphy, N., Bahl, P., Salio, M., Maskell, K., Piris, J., et al., 2007. Modulation of CD103 expression on human colon carcinoma-specific CTL. J Immunol 178, 2908–2915.

Le Floch, A., Jail, A., Vergnon, I., Le Maux, Chansac B., Lazar, V., Bismuth, G., et al., 2007. Alpha beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med 204, 559–570.

French, J.J., Cresswell, J., Wong, W.K., Seymour, K., Charney, R.M., Kirby, J.A., 2002. T cell adhesion and cytokinesis of pancreatic cancer cells: a role for E-cadherin in immunotherapy? Br J Cancer 87, 1034–1041.

Webb, J.R., Wick, D.A., Nielsen, J.S., Tran, E., Milne, M., McMartin, E., et al., 2010. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 integrin) in high-grade serous ovarian cancer. Gynecol Oncol 118, 228–236.

Franciskiewicz, K., Le Floch, A., Jail, A., Vigant, F., Robert, T., Vergnon, I., et al., 2009. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res 69, 6249–6255.

van Gool, I.C., Eggink, F.A., Freeman-Mills, L., Stelloo, E., Marchi, E., de Bruyn, M., et al., 2015. POLE proofreading mutations elicit an antitumor immune response in endometrial Cancer. Clin Cancer Res 21, 3347–3355.

Noordhuis, M.G., Ejsjink, J.J., Ten Hoor, K.A., Roossink, F., Hollema, H., Arts, H.J., et al., 2009. Expression of epidermal growth factor receptor (EGFR) and activated EGF predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 15, 7389–7397.

Mootha, V.K., Lindgren, C.M., Eriksson, X.F., Subramanian, A., Sihag, S., Lehar, J., et al., 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are co-ordinately downregulated in human diabetes. Nat Genet 34, 267–273.

Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., et al., 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15455–15500.

Djenidi, F., Adam, J., Goubar, A., Dargeau, A., Meurisse, G., de Montereau, V., et al., 2015. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol 194, 3475–3486.

Franciskiewicz, K., Le Floch, A., Boutet, M., Vergnon, I., Schmitt, A., Mami-Chouaib, F., 2013. CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions. Cancer Res 73, 617–628.

Webb, J.R., Milne, K., Watson, P., Deleeuw, R.J., Nelson, B.H., 2014. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res 20, 434–444.

Komdeur, F.L., Piens, T.M., van de Wall, S., Plat, A., Wisman, G.B.A., Hollemans, H., et al., 2017. CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncoimmunology 6, e1338230.

Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A.C., et al., 2013. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795.

Neville, L.F., Mathiaki, G., Bagasa, O., 1997. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 8, 207–219.

Farber, J.M., 1997. Mig and IP-10: CXCR3 chemokines that target lymphocytes. J Leukoc Biol 61, 246–257.

Ma, H.Y., Liu, X.Z., Liang, C.M., 2016. Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. World J Gastroenterol 22, 6619–6628.

Fuke, J., Karlsson, M.C., 2012. TGF-beta-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 22, 455–461.

Dehui, C., Bo, P., Qiang, T., Lihua, S., Fang, L., Shi, J., et al., 2014. Enhanced invasion of lung adenocarcinoma cells after co-culture with THP-1-derived macrophages via the induction of EMT by IL-6. Immunol Lett 160, 1–10.

Lakshmi Narendra, B., Eshvendar Reddy, K., Shantikumar, S., Ramakrishna, S., 2013. Immune system: a double-edged sword in cancer. Inflamms Res 62, 823–834.

Rosso, M., Majem, B., Devis, L., Lapyczyk, L., Beso, M.J., Llaurado, M., et al., 2017. E-cadherin: a determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness. PLoS One 12, e0184439.

Hoos, A., Urist, M.J., Stojadinovic, A., Mastorides, S., Dudas, M.E., Leung, D.H., et al., 2001. Validation of tissue microarrays for immunohistochemical profiling of cancer: specimens using the example of human fibroblastic tumors. Am J Pathol 158, 1245–1251.

Henriksen, K.L., Rasmussen, B.B., Lykkeforsfeld, A.E., Moller, S., Ejlertsen, B., Mouridsen, H.T., 2007. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 60, 397–404.

Ganesan, A.P., Clarke, J., Wood, O., Garrido-Martin, E.M., Chee, S.J., Mellovs, T., et al., 2017. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol 18 (8), 940–950.

Mihalier J.T., Toma C, Yu B, Zhang K, Omilusik K, Pan AT, et al. Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours. Nature. 14;7(884):253–257.

Quinn E, Hawkins N, Yip YL, Suter C, Ward R. CD103+ intraepithelial lymphocytes—a unique population in microsatellite unstable sporadic colorectal cancer. Eur J Cancer. 39(4):469–75.